Since sacituzumab govitecan, an approved Trop2-targeting drug, is now available, we sought to examine the expression of Trop2 by performing a systemic immunohistochemistry (IHC) screening on a tissue microarray (TMA) derived from 92 patients with newly diagnosed or refractory or relapsed (r/r) DLBCL. The gene discussed is TACSTD2; the disease is diffuse large B-cell lymphoma.